Blocking TNF to Enhance Immune Response in Melanoma Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of blocking Tumor Necrosis Factor alpha (TNF) to improve the immune response in patients with melanoma who are being treated with immune checkpoint inhibitors (ICI). It aims to clarify the pharmacodynamic impact of TNF inhibitors on immune and clinical responses, particularly in patients who do not respond to ICI therapy or experience severe immune-related adverse events. The study builds on previous findings that suggest TNF inhibitors can enhance the efficacy of ICIs and reduce adverse effects. Patients participating in this observational study are already enrolled in two related clinical trials, TICIMEL and MELANFalpha.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Inclusion in TICIMEL clinical trial (NCT03293784),
* Inclusion in MELANFα trial (NCT03348891)

Exclusion Criteria:

* NA

Where it's running

• Institut Claudius Regaud
  Toulouse, France Recruiting

Study contacts

• Principal investigator: Bruno SEGUI, Pr — Cancer Research Center of Toulouse
• Study coordinator: Bruno SEGUI, Pr
• Email: bruno.segui@inserm.fr
• Phone: +33 (0)5 82 74 16 21

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating OBX-115 for advanced solid tumors

  This study is testing a new treatment called OBX-115 to see if it can help adults with advanced solid tumors like metastatic melanoma and non-small cell lung cancer feel better and live longer.

  Recruiting at 13 sites Phase 1/2 Obsidian Therapeutics, Inc. · Tucson, Arizona and 13 other locations · NCT06060613

• Melanoma treatment with immunotherapy guided by serial ctDNA testing

  This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07930182

• Non-invasive skin-tape test to detect melanoma using methylation biomarkers

  A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.

  Recruiting at 4 sites Mitra Bio · Ghent and 4 other locations · NCT07883954

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• BL-M08D treatment in melanoma and other solid tumors

  A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07841925

• Aggressive lipid lowering in melanoma patients starting immune checkpoint therapy

  This trial tests whether lowering cholesterol aggressively can reduce heart artery disease risk in melanoma patients who are just beginning immune checkpoint therapy.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT07704918

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.